Key Takeaways ENTX unveiled promising PK data for oral GLP-2 analog OPK-8801003 in SBS.ENTX's therapy showed 15-hour half-life, 18x longer than current injection option.ENTX's oral approach could improve adherence versus burdensome daily injections.Entera Bio Ltd. (ENTX) recently reported encouraging pharmacokinetic data, underscoring the potential of its first-in-class oral GLP-2 analog therapy for patients with short bowel syndrome (SBS). The findings, presented at the 47th European Society for Clinical N ...